A5071873190- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Ubiquitin and proteasome pathways
- Protein Degradation and Inhibitors
- RNA Research and Splicing
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Peptidase Inhibition and Analysis
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Retinoids in leukemia and cellular processes
- Cytokine Signaling Pathways and Interactions
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- RNA modifications and cancer
- Multiple Myeloma Research and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Histiocytic Disorders and Treatments
- Glycosylation and Glycoproteins Research
- T-cell and Retrovirus Studies
Icahn School of Medicine at Mount Sinai
2015-2024
Memorial Sloan Kettering Cancer Center
2012-2023
Tisch Cancer Institute
2020-2023
Tisch Hospital
2023
Mount Sinai Health System
2016-2021
Mount Sinai Hospital
2017-2021
Mount Sinai Hospital
2020
Mount Sinai Hospital
2020
Cancer Genetics (United States)
2002-2014
Cancer Research And Biostatistics
2014
Numerous studies have established a causal link between aberrant mammalian target of rapamycin (mTOR) activation and tumorigenesis, indicating that mTOR inhibition may therapeutic potential. In this study, we show its analogs activate the MAPK pathway in human cancer, what represents novel mTORC1-MAPK feedback loop. We found tumor samples from patients with biopsy-accessible solid tumors advanced disease treated RAD001, derivative, showed an administration schedule–dependent increase...
Genetically engineered mouse models are powerful tools for studying cancer genes and validating targets therapy. We previously used a lymphoma model to demonstrate that the translation initiation factor eIF4E is potent oncogene in vivo. Using same model, we now show oncogenic activity of correlates with its ability activate become phosphorylated on Ser 209. Furthermore, constitutively activated MNK1, an 209 kinase, promotes tumorigenesis manner similar eIF4E, dominant-negative MNK mutant...
PURPOSE In studies of diffuse large B-cell lymphoma, positron emission tomography with [(18)F]fluorodeoxyglucose (FDG-PET) performed after two to four cycles chemotherapy has demonstrated prognostic significance. However, some patients treated immunochemotherapy experience a favorable long-term outcome despite positive interim FDG-PET scan. To clarify the significance scans, we prospectively studied FDG-positive disease within risk-adapted sequential program. PATIENTS AND METHODS From March...